Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BPTSY
Biophytis
$1.38
$1.95
$1.38
$8.00
$484K0.842,149 shs5 shs
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
$1.16
$0.16
$3.32
$330K1.6611,347 shs107,749 shs
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
$0.13
+3.6%
$0.17
$1.75
$63.90
$308K2.15134,123 shs5.36 million shs
Smart for Life, Inc. stock logo
SMFL
Smart for Life
$0.04
$0.01
$0.00
$3.31
$284K1.385,001 shs1 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BPTSY
Biophytis
0.00%0.00%-20.23%-58.93%-80.03%
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
0.00%0.00%0.00%0.00%-90.67%
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
+3.59%-6.81%-24.64%-63.89%-93.12%
Smart for Life, Inc. stock logo
SMFL
Smart for Life
0.00%+128.57%+0.25%+1,381.48%-98.71%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BPTSY
Biophytis
N/AN/AN/AN/AN/AN/AN/AN/A
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BPTSY
Biophytis
0.00
N/AN/AN/A
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
0.00
N/AN/AN/A
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
0.00
N/AN/AN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BPTSY
Biophytis
N/AN/AN/AN/A($16.18) per shareN/A
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/AN/AN/AN/A($8.29) per shareN/A
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
N/AN/AN/AN/A$7.21 per shareN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
$11.11M0.03N/AN/A($17.10) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BPTSY
Biophytis
-$18.43MN/A0.00N/AN/AN/AN/AN/A
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
-$26.90M-$3.50N/AN/AN/AN/AN/A-277.46%N/A
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
-$4MN/A0.00N/AN/A-179.05%-108.14%N/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
-$22.68MN/A0.00N/AN/AN/AN/AN/A

Latest SMFL, BPTSY, KRBP, and MYMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/23/2025Q2 2024
Smart for Life, Inc. stock logo
SMFL
Smart for Life
N/A-$2.41N/A-$2.34N/A$0.88 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BPTSY
Biophytis
N/AN/AN/AN/AN/A
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/AN/AN/AN/AN/A
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
N/AN/AN/AN/AN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BPTSY
Biophytis
N/A
0.41
N/A
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
N/A
0.16
0.22
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
N/A
0.62
0.62
Smart for Life, Inc. stock logo
SMFL
Smart for Life
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
BPTSY
Biophytis
0.05%
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
10.91%
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
9.64%
Smart for Life, Inc. stock logo
SMFL
Smart for Life
28.39%

Insider Ownership

CompanyInsider Ownership
BPTSY
Biophytis
3.70%
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
20.59%
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
2.12%
Smart for Life, Inc. stock logo
SMFL
Smart for Life
31.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
BPTSY
Biophytis
30351,000338,000N/A
Kiromic BioPharma, Inc. stock logo
KRBP
Kiromic BioPharma
601.57 million1.22 millionNot Optionable
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
62.37 million2.32 millionOptionable
Smart for Life, Inc. stock logo
SMFL
Smart for Life
1107.09 million4.84 millionNot Optionable

Recent News About These Companies

Smart for Life Inc. (SMFL) Analyst Research
SMART High School Common App Workshop
7 Smart Tips for Living a Joyful and Purpose-Driven Life
Smart supramolecular assemblies
HRT Financial LP Acquires New Stake in Smart for Life Inc

Media Sentiment Over Time

Biophytis NASDAQ:BPTSY

$1.38 0.00 (0.00%)
As of 06/27/2025

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Kiromic BioPharma stock logo

Kiromic BioPharma NASDAQ:KRBP

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

MyMD Pharmaceuticals stock logo

MyMD Pharmaceuticals NASDAQ:MYMD

$0.13 +0.00 (+3.59%)
As of 06/27/2025

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Smart for Life stock logo

Smart for Life NASDAQ:SMFL

$0.04 0.00 (0.00%)
As of 06/27/2025

Smart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements under the Smart for Life brand; dietary supplements; and nutritional products, including whey protein isolate powder, tablet supplements for joint health, nitric oxide, post workout blends, Omega-3 supplements, and pre-workout supplements under the Sports Illustrated Nutrition brand for athletes and active lifestyle consumers. The company also provides various nutritional products, including antioxidant rich supplements, plant-based proteins, alkalizing nutrients, and weight management products. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Boca Raton, Florida.